Updated on 27 February 2015
MRX-I is an oral oxazolidinone antibiotic designed to treat infections
Singapore: MicuRx Pharmaceuticals, US and China based biopharmaceutical company developing next-generation antibiotics, has recieved USFDA approval to initiate Phase 2 clinical study in the United States for its lead drug candidate MRX-I, an oral oxazolidinone antibiotic designed to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
The Phase 2 double-blind, multi-center, active comparator-controlled clinical trial will enroll over 120 patients with acute bacterial skin and skin structure infections (ABSSSI) at multiple centers in the United States. Patients will be randomized to receive MRX-I or Zyvox for a treatment period of up to ten days.
"We are pleased to initiate Phase 2 clinical trial in the United States. This complements the ongoing Phase 2 study of MRX-I in China and represents a significant milestone in our global development strategy, as MicuRx creates new antibiotics to address urgent medical needs," said Dr Zhengyu Yuan, president and CEO, MicuRx Pharmaceuticals. "This dual-country approach will allow MicuRx to maximize the commercial potential of MRX-I both in the US and China."